King-Jones Heidy
See Remarks
King-Jones Heidy has filed 1 SEC Form 4 filing (7 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Sep 4, 2026.
On the most recent filing, King-Jones Heidy is listed as See Remarks at Spyre Therapeutics, Inc. Inside the rolling window, King-Jones Heidy reported no open-market purchases and 2 open-market sales totaling $2.5M in SYRE. The largest disclosed transaction in the window is a sale of 27,999 SYRE shares on Sep 1, 2026, worth $2.4M.
Companies traded
Other insiders at SYRE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.5M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has King-Jones Heidy made?
King-Jones Heidy has filed 1 SEC Form 4 filing (7 transaction rows) across 1 company since 2026.
Which companies does King-Jones Heidy trade?
King-Jones Heidy has filed SEC Form 4 disclosures for 1 company, including SYRE.
When was King-Jones Heidy's most recent SEC Form 4 filing?
King-Jones Heidy's most recent SEC Form 4 filing on Tracefour is dated Sep 4, 2026.
What is King-Jones Heidy's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, King-Jones Heidy is listed as See Remarks.
What is King-Jones Heidy's total buy and sell value in the current window?
Inside the rolling retention window, King-Jones Heidy bought $0 and sold $2.5M based on SEC Form 4 filings.
What was King-Jones Heidy's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 27,999 SYRE shares on 2026-09-01, worth $2.4M, per SEC Form 4 filings.